LLY

1,023.98

-2.1%↓

JNJ

238.23

-0.2%↓

ABBV

222.29

-0.37%↓

NVS

158.25

+0.92%↑

MRK

117.15

-0.43%↓

LLY

1,023.98

-2.1%↓

JNJ

238.23

-0.2%↓

ABBV

222.29

-0.37%↓

NVS

158.25

+0.92%↑

MRK

117.15

-0.43%↓

LLY

1,023.98

-2.1%↓

JNJ

238.23

-0.2%↓

ABBV

222.29

-0.37%↓

NVS

158.25

+0.92%↑

MRK

117.15

-0.43%↓

LLY

1,023.98

-2.1%↓

JNJ

238.23

-0.2%↓

ABBV

222.29

-0.37%↓

NVS

158.25

+0.92%↑

MRK

117.15

-0.43%↓

LLY

1,023.98

-2.1%↓

JNJ

238.23

-0.2%↓

ABBV

222.29

-0.37%↓

NVS

158.25

+0.92%↑

MRK

117.15

-0.43%↓

Kodu・Aktsiate loetelu・Fate Therapeutics Inc

Fate Therapeutics Inc

Suletud

SektorTervishoid

1.09 -2.68

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

1.08

Max

1.16

Põhinäitajad
By Trading Economics
Sissetulek	1.8M -32M
Müük	-166K 1.7M
Kasumimarginaal	-1,852.384
Töötajad	181
EBITDA	7.9M -29M

Soovitused
By TipRanks
Soovitused	Osta
12 kuu keskmine prognoos	+335.71% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	3. märts 2026

Turustatistika
By TradingEconomics
Turukapital	3.5M 129M
Eelmine avamishind	3.77
Eelmine sulgemishind	1.09

Uudiste sentiment

By Acuity

50%

149 / 352 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bearish Evidence

0.9101 / 1.14 Toetus ja vastupanu

Fate Therapeutics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

10. veebr 2026, 23:26 UTC

Suurimad hinnamuutused turgudel

Moderna Stock Slips After FDA Refuses Flu Vaccine Review

10. veebr 2026, 22:31 UTC

Tulu

Correction to America Movil 4Q Profit Article

10. veebr 2026, 22:22 UTC

Tulu

America Movil 4Q Profit Jumps on Lower Financial Costs

10. veebr 2026, 23:51 UTC

Market Talk

Tulu

Commonwealth Bank's Margin Management Gives It a Platform -- Market Talk

10. veebr 2026, 23:42 UTC

Market Talk

Gold Rises Amid Fed Rate-Cut Prospects -- Market Talk

10. veebr 2026, 23:40 UTC

Market Talk

Tulu

Commonwealth Bank Bear Says 1H Result Looks Strong -- Market Talk

10. veebr 2026, 23:21 UTC

Market Talk

Ford Says EV Shift Was Driven by Demand Changes -- Market Talk

10. veebr 2026, 23:21 UTC

Market Talk

Global Equities Roundup: Market Talk

10. veebr 2026, 22:17 UTC

Market Talk

Australia's One Nation Now Commands Working Class Vote -- Market Talk

10. veebr 2026, 22:15 UTC

Tulu

Humana Earnings Will Shed More Light on Medicare Prospects -- Barrons.com

10. veebr 2026, 22:10 UTC

Tulu

Intact Financial 4Q Book Value Per Share Was C$107.35 >IFC.T

10. veebr 2026, 22:10 UTC

Tulu

Intact Financial Raises Qtr Dividend to C$1.47 >IFC.T

10. veebr 2026, 22:09 UTC

Tulu

Intact Financial 4Q Combined Ratio Was 85.9% >IFC.T

10. veebr 2026, 22:09 UTC

Tulu

Intact Financial 4Q Adj EPS C$5.50 >IFC.T

10. veebr 2026, 22:01 UTC

Tulu

Intact Financial 4Q EPS C$5.24 >IFC.T

10. veebr 2026, 21:54 UTC

Tulu

James Hardie Industries Sees FY26 Total Adjusted EBITDA $1.232B to $1.263B >JHX

10. veebr 2026, 21:53 UTC

Tulu

Robinhood Stock Tumbles as Crypto-Related Revenue Falls Short of Expectations -- Barrons.com

10. veebr 2026, 21:51 UTC

Tulu

James Hardie Industries Sees FY26 Free Cash Flow at Least $200M

10. veebr 2026, 21:51 UTC

Tulu

Gilead Earnings Surprise. Why The Stock Is Tumbling Anyway. -- Barrons.com

10. veebr 2026, 21:51 UTC

Tulu

James Hardie Industries: Focused on the Achievement of $125 M Target >JHX

10. veebr 2026, 21:51 UTC

Tulu

James Hardie Industries: Integration and Cost Synergies Ahead of Schedule >JHX

10. veebr 2026, 21:51 UTC

Tulu

Omandamised, ülevõtmised, äriostud

Evolution Net Debt A$362 Million at Dec. 31 Vs A$1.29 Billion Year Earlier

10. veebr 2026, 21:50 UTC

Tulu

Omandamised, ülevõtmised, äriostud

Evolution: Gearing 6% at Dec. 31, From 23% a Year Earlier

10. veebr 2026, 21:50 UTC

Tulu

James Hardie Industries 3Q EPS 12c >JHX

10. veebr 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

10. veebr 2026, 21:50 UTC

Tulu

James Hardie Industries 3Q Adj EPS 24c >JHX

10. veebr 2026, 21:49 UTC

Tulu

James Hardie Industries 3Q Sales $1.24B >JHX

10. veebr 2026, 21:49 UTC

Tulu

Omandamised, ülevõtmised, äriostud

Evolution 1H Operating Mine Cash Flow a Record A$1.73 Billion

10. veebr 2026, 21:48 UTC

Tulu

Omandamised, ülevõtmised, äriostud

Evolution 1H Ebitda A$1.56 Billion, Up 59% On-Year

10. veebr 2026, 21:47 UTC

Tulu

Omandamised, ülevõtmised, äriostud

Evolution 1H Revenue A$2.79 Billion, Up 37% On-Year

Võrdlus sarnastega

Hinnamuutus

Fate Therapeutics Inc Prognoos

Hinnasiht

By TipRanks

335.71% tõus

12 kuu keskmine prognoos

Keskmine 4.88 USD 335.71%

Kõrge 8 USD

Madal 2 USD

Põhineb 6 Wall Streeti analüütiku instrumendi Fate Therapeutics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

6 ratings

Osta

Hoia

Müü

Põhineb 6 analüütiku instrumendi Fate Therapeutics Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

0.9101 / 1.14Toetus ja vastupanu

Recent bearish events outweigh bullish events.

All events are bullish.

There are no events.

Sentiment

By Acuity

149 / 352 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Fate Therapeutics Inc

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.